Nathan Papa

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/3922170/publications.pdf

Version: 2024-02-01

59	2,360 citations	471509 17 h-index	214800 47 g-index
papers	Citations	II-IIIQEX	g-mdex
59 all docs	59 docs citations	59 times ranked	3151 citing authors

#	Article	IF	CITATIONS
1	Sensitivity, Specificity, and Predictors of Positive 68 Ga–Prostate-specific Membrane Antigen Positron Emission Tomography in Advanced Prostate Cancer: A Systematic Review and Meta-analysis. European Urology, 2016, 70, 926-937.	1.9	819
2	Gallium-68 Prostate-specific Membrane Antigen Positron Emission Tomography in Advanced Prostate Cancer—Updated Diagnostic Utility, Sensitivity, Specificity, and Distribution of Prostate-specific Membrane Antigen-avid Lesions: A Systematic Review and Meta-analysis. European Urology, 2020, 77, 403-417.	1.9	614
3	The Additive Diagnostic Value of Prostate-specific Membrane Antigen Positron Emission Tomography Computed Tomography to Multiparametric Magnetic Resonance Imaging Triage in the Diagnosis of Prostate Cancer (PRIMARY): A Prospective Multicentre Study. European Urology, 2021, 80, 682-689.	1.9	181
4	Globalization of Continuing Professional Development by Journal Clubs via Microblogging: A Systematic Review. Journal of Medical Internet Research, 2015, 17, e103.	4.3	100
5	The current use of active surveillance in an Australian cohort of men: a pattern of care analysis from the <scp>V</scp> ictorian Prostate Cancer Registry. BJU International, 2015, 115, 50-56.	2.5	80
6	Extended-spectrum beta-lactamase-producing Enterobacteriaceae in hospital urinary tract infections: incidence and antibiotic susceptibility profile over 9Âyears. World Journal of Urology, 2016, 34, 1031-1037.	2.2	39
7	Urolithiasis Treatment in Australia: The Age of Ureteroscopic Intervention. Journal of Endourology, 2016, 30, 1194-1199.	2.1	35
8	Intermittent versus continuous androgen deprivation therapy for advanced prostate cancer. Nature Reviews Urology, 2020, 17, 469-481.	3.8	29
9	Vancomycin resistant enterococci in urine cultures: Antibiotic susceptibility trends over a decade at a tertiary hospital in the United Kingdom. Investigative and Clinical Urology, 2016, 57, 129.	2.0	27
10	A contemporary, nationwide analysis of surgery and radiotherapy treatment for prostate cancer. BJU International, 2019, 124, 31-36.	2.5	27
11	PSA-based machine learning model improves prostate cancer risk stratification in a screening population. World Journal of Urology, 2021, 39, 1897-1902.	2.2	27
12	Incidence and risk factors of venous thromboembolism after pelvic uroâ€oncologic surgery – a single center experience. BJU International, 2016, 117, 50-53.	2.5	25
13	Factors affecting the timeliness and adequacy of haematuria assessment in bladder cancer: a systematic review. BJU International, 2017, 119, 10-18.	2.5	23
14	Laparoscopic lens fogging: solving a common surgical problem in standard and robotic laparoscopes via a scientific model. Surgical Endoscopy and Other Interventional Techniques, 2018, 32, 1600-1606.	2.4	20
15	The PRIMARY Score: Using intra-prostatic PSMA PET/CT patterns to optimise prostate cancer diagnosis Journal of Nuclear Medicine, 2022, , jnumed.121.263448.	5.0	20
16	Multiparametric magnetic resonance imaging for prostate cancer—a comparative study including radical prostatectomy specimens. World Journal of Urology, 2017, 35, 935-941.	2.2	19
17	Primary tumour PSMA intensity is an independent prognostic biomarker for biochemical recurrence-free survival following radical prostatectomy. European Journal of Nuclear Medicine and Molecular Imaging, 2022, 49, 3289-3294.	6.4	18
18	Evaluation of pelvic floor muscle strength before and after robotic-assisted radical prostatectomy and early outcomes on urinary continence. Journal of Robotic Surgery, 2016, 10, 331-335.	1.8	17

#	Article	IF	Citations
19	The impact of the global bacille Calmette–Guérin shortage on treatment patterns: populationâ€based data. BJU International, 2018, 121, 169-172.	2.5	17
20	Adjuvant therapies for non-muscle-invasive bladder cancer: advances during BCG shortage. World Journal of Urology, 2022, 40, 1111-1124.	2.2	17
21	Changing trends in surgical management of renal tumours from 2000 to 2016: a nationwide study of Medicare claims data. ANZ Journal of Surgery, 2020, 90, 48-52.	0.7	16
22	Predictors of delay to cystoscopy and adequacy of investigations in patients with haematuria. BJU International, 2017, 119, 19-25.	2.5	15
23	Patients' Perspectives of Accessibility and Digital Delivery of Factual Content Provided by Official Medical and Surgical Specialty Society Websites: A Qualitative Assessment. Interactive Journal of Medical Research, 2015, 4, e7.	1.4	14
24	Lymph node yield in node-negative patients predicts cancer specific survival following radical cystectomy for transitional cell carcinoma. Investigative and Clinical Urology, 2017, 58, 416.	2.0	11
25	Patterns of care for prostate cancer treatment and improving outcomes – are national registries the answer?. BJU International, 2021, 128 Suppl 1, 6-8.	2.5	11
26	Declining use of radical prostatectomy and pelvic lymphadenectomy despite more robotics: National population data over 15 years. Asia-Pacific Journal of Clinical Oncology, 2020, 16, e118-e124.	1.1	10
27	High prostateâ€specific membrane antigen (<scp>PSMA) positron emission tomography (PET)</scp> maximum standardized uptake value in men <scp>with Plâ€RADS</scp> score 4 or 5 confers a high probability of significant prostate cancer. BJU International, 2022, 130, 5-7.	2.5	10
28	Consistency of written postâ€operative patient information for common urological procedures. ANZ Journal of Surgery, 2015, 85, 941-945.	0.7	9
29	Poor Employment Conditions Adversely Affect Mental Health Outcomes Among Surgical Trainees. Journal of Surgical Education, 2018, 75, 156-163.	2.5	9
30	Predictors of realâ€world utilisation of docetaxel combined with androgen deprivation therapy in metastatic hormoneâ€sensitive prostate cancer. Internal Medicine Journal, 2022, 52, 1339-1346.	0.8	9
31	Australian patterns of prostate cancer care: Are they evolving?. Prostate International, 2016, 4, 20-24.	2.3	8
32	Knowledge of smoking as a risk factor for disease among urology clinic patients in Australia. World Journal of Urology, 2018, 36, 1219-1224.	2.2	8
33	Trends in the surgical treatment of benign prostatic hyperplasia in a tertiary hospital. ANZ Journal of Surgery, 2018, 88, 95-99.	0.7	7
34	How Does Age Affect Urinary Continence following Robot-Assisted Radical Prostatectomy? A Prospective Multi-Institutional Study Using Independently Collected, Validated Questionnaires. Journal of Urology, 2022, 207, 1048-1056.	0.4	7
35	A longitudinal study evaluating interim assessment of neoadjuvant chemotherapy for bladder cancer. BJU International, 2022, 130, 306-313.	2.5	6
36	A Whole of Population, Multiuser Series of High-Intensity Focused Ultrasound for Management of Localized Prostate Cancer: Outcomes and Implications. Journal of Endourology, 2015, 29, 844-849.	2.1	5

#	Article	IF	CITATIONS
37	Supervisor volume affects oncological outcomes of trainees performing open radical prostatectomy. ANZ Journal of Surgery, 2016, 86, 249-254.	0.7	5
38	Patterns of primary staging for newly diagnosed prostate cancer in the era of prostate specific membrane antigen positron emission tomography: A populationâ€based analysis. Journal of Medical Imaging and Radiation Oncology, 2021, 65, 649-654.	1.8	4
39	Open versus Endovascular Abdominal Aortic Aneurysm Repair in the Australian Private Sector Over Twenty Years. Journal of Endovascular Therapy, 2021, 28, 844-851.	1.5	4
40	Trends in percutaneous renal biopsy: The evolving diagnostic pathway for the small renal mass. Urology Annals, 2018, 10, 237.	0.6	4
41	Cribriform pattern disease overâ€represented in pelvic lymph node metastases identified on ⁶⁸ GA PSMAâ€PET/CT. BJUI Compass, 2022, 3, 371-376.	1.3	4
42	Predictors of erectile dysfunction after transperineal template prostate biopsy. Investigative and Clinical Urology, 2021, 62, 159.	2.0	3
43	Continuous bladder irrigation after transurethral resection of nonâ€muscle invasive bladder cancer for prevention of tumour recurrence: a systematic review. ANZ Journal of Surgery, 2021, 91, 2592-2598.	0.7	3
44	Quantifying the effect email reminders have on patient reported outcome measure returns in a large prostate cancer registry. Journal of Patient-Reported Outcomes, 2022, 6, 19.	1.9	3
45	Bladder cancer diagnosis during haematuria investigation – implications for practice guidelines. BJU International, 2017, 119, 53-54.	2.5	2
46	Reply to Fabio Zattoni, Filiberto Zattoni, and Laura Evangelista's Letter to the Editor re: Marlon Perera, Nathan Papa, Daniel Christidis, et al. Sensitivity, Specificity, and Predictors of Positive 68 Ga–Prostate-specific Membrane Antigen Positron Emission Tomography in Advanced Prostate Cancer: A Systematic Review and Meta-analysis. Eur Urol 2016;70:926–37. European Urology, 2017, 71, e66-e67.	1.9	2
47	Body size and dietary risk factors for aggressive prostate cancer: a case–control study. Cancer Causes and Control, 2019, 30, 1301-1312.	1.8	2
48	Trends in the Uptake of Diagnostic Multi-Parametric MRI of the Prostate With Federal Funding: Australia Population Data. Urology, 2021, 155, 9-11.	1.0	2
49	Testicular Cancer in Trans People Using Feminising Hormone Therapy– A Brief Review. Urology, 2021, , .	1.0	2
50	Mapping disadvantage: identifying inequities in functional outcomes for prostate cancer survivors based on geography. BMC Cancer, 2022, 22, 283.	2.6	2
51	The continuing impacts of the <scp>COVID</scp> â€19 pandemic on diagnosis and surgical prostate cancer management: a populationâ€based analysis. ANZ Journal of Surgery, 2022, 92, 950-952.	0.7	2
52	Advancing Traditional Prostate-specific Antigen Kinetics in the Detection of Prostate Cancer: A Machine Learning Model. European Urology Focus, 2022, 8, 1204-1210.	3.1	2
53	Emerging trends in prostate cancer literature: medical progress or marketing hype?. BJU International, 2016, 117, 14-16.	2.5	1
54	Re: Laboratory Risk Indicator for Necrotizing Fasciitis score for early diagnosis of necrotizing fasciitis in Darwin. ANZ Journal of Surgery, 2017, 87, 1061-1061.	0.7	1

#	Article	IF	CITATIONS
55	A multi-level spatio-temporal analysis on prostate cancer outcomes. Cancer Epidemiology, 2021, 72, 101939.	1.9	1
56	Selfâ€reported lack of energy or feeling depressed 12Âmonths after treatment in men diagnosed with prostate cancer within a populationâ€based registry. Psycho-Oncology, 2021, , .	2.3	1
57	Knowledge and insights from a maturing international clinical quality registry. Journal of the American Medical Informatics Association: JAMIA, 2022, 29, 964-969.	4.4	1
58	A novel technique for measuring intraoperative bladder neck and urethral dimensions during robotic-assisted radical prostatectomy. Canadian Urological Association Journal, 2021, 15, E510-E512.	0.6	0
59	Setting up the Prostate Cancer Outcomes Registry of New Zealand: reflecting and influencing clinical practice. New Zealand Medical Journal, 2021, 134, 79-88.	0.5	0